Randomized Trialhigh evidence
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Lancet (London, England)·March 21, 2026·PMID 41765029
Why it mattersOrforglipron is a novel non-peptide oral GLP-1 agonist that does not require fasting or water restrictions, potentially simplifying dosing. This trial provides head-to-head efficacy and safety data against the established oral semaglutide, informing its role in diabetes management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled